Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
In IBS, early studies suggest reductions in abdominal pain and symptom burden, though these therapies are not first-line
Loreto, A., Antoniou, C., Merlini, E., Gilley, J
The pharmaceutical business model is naturally vulnerable to such competitive price declines, combining as it does high upfront investment costs and low production costs to make each dose
Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, GSK, Regeneron Pharmaceuticals Inc., Pfizer Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, ZEALAND PHARMA, Hanmi Pharm
US$ 20.51
US$ 28.03
US$ 23.00
